LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

被引：0
|
作者：
Jackson, D. [1 ]
Lee, J. M. [2 ]
Adams, J. [1 ]
Gordois, A. [1 ]
机构：
[1] IMS Hlth, St Leonards, NSW, Australia
[2] Sanofi Aventis Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74342-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [11] Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer
    Livi, L.
    Meattini, I.
    Cardillo, C. De Luca
    Scotti, V.
    Agresti, B.
    Franzese, C.
    Sanchez, L.
    Nori, J.
    Bertocci, S.
    Cassani, S.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 36 - 39
  • [12] Docetaxel plus cyclophosphamide in adjuvant breast cancer - In reply
    Jones, Stephen E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4327 - 4327
  • [13] The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    CURRENT ONCOLOGY, 2011, 18 (06) : E288 - E296
  • [14] Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer
    Martin, Miguel
    WOMENS HEALTH, 2006, 2 (04) : 527 - 537
  • [15] HER2 expression-based approach of neoadjuvant chemotherapy with doxorubicin plus cyclophosphamide or docetaxel plus cyclophosphamide for operable breast cancer
    Ishikawa, Takashi
    Shimizu, Daisuke
    Takeshi, Sasaki
    Tanabe, Mikiko
    Ota, Ikuko
    Kito, Ayako
    Nozawa, Akinori
    Kawachi, Kae
    Morita, Satoshi
    Chishima, Takashi
    Ichikawa, Yasushi
    CANCER RESEARCH, 2009, 69
  • [16] A feasibility study of docetaxel in combination with anthracycline and cyclophosphamide or docetaxel followed by anthracycline plus cyclophosphamide in adjuvant therapy for operable breast
    Shen, ZZ
    Liu, GY
    Shao, ZM
    Wang, SM
    Zhang, B
    Jiang, ZF
    He, PQ
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S107 - S107
  • [17] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Lee, Sang Gyu
    Jee, Young Geon
    Chung, Hyun Chul
    Kim, Sung-Bae
    Ro, Jungsil
    Im, Young-Hyuck
    Im, Seock-Ah
    Seo, Jae Hong
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595
  • [18] Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: A cost-effectiveness and cost-utility analysis
    Wolowacz, Sorrel E.
    Cameron, David A.
    Tate, Helen C.
    Bagust, Adrian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 925 - 933
  • [19] Comparing doxorubicin plus cyclophosphamide (four courses) and CMF (three more courses) with doxorubicin plus cyclophosphamide (four courses) and paclitaxel plus epirubicin (three courses) as adjuvant therapy for operable breast cancer
    Ghavamzadeh, A.
    Najafi, S. Nadjar
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [20] Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients.
    Coskun, HS
    Er, O
    Ozkan, M
    Eser, B
    Altinbas, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
12345